Chemotherapy and immunotherapy after surgery for certain stomach and colon cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a chemotherapy followed by an immunotherapy drug (tislelizumab) for people with stomach or colon cancer that has certain genetic markers. It aims to prevent the cancer from coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You had surgery to remove all visible cancer (R0 resection) for stomach, gastroesophageal junction, or colon cancer.
- Your tumor has a specific genetic change: dMMR, MSI-H, or a POLE/POLD1 mutation.
- Your cancer was at a certain stage after surgery: stage III for stomach or junction cancer, or T1-3N2M0 or T4N+M0 for colon cancer.
- You have not had chemotherapy or radiation for this cancer before surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy before and after surgery can help treat stomach or gastroesophageal junction cancer. It is for people whose cancer has not spread to other organs and who are well enough to have surgery.
This trial tests a combination of an immunotherapy drug (tislelizumab) and chemotherapy after surgery to prevent stomach cancer from coming back in older patients. It may be a good option for people who have had their cancer completely removed and are in good overall health.
This trial tests whether giving immunotherapy after surgery can help prevent stomach cancer from coming back. It is for patients whose tumors show certain markers that suggest immunotherapy may work well.
This Phase 2 trial studies giving tislelizumab (an immune therapy) together with pre-surgery chemoradiation for locally advanced stomach or GEJ (esophagus-stomach junction) adenocarcinoma. It compares this approach to the standard treatment (chemoradiation plus surgery) to see if it improves outcomes.
This trial tests a combination of low-dose radiotherapy, chemotherapy, and an immunotherapy drug (tislelizumab) before and after surgery for locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
Hear when a new Gastric trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.